trial · primary record
Ritlecitinib
Stable Nonsegmental Vitiligo
| Phase | Phase 3 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 1571 |
| Primary completion | 2027-07-30 |
| Primary endpoint | US only Co-Primary Endpoints: Response based on Facial Vitiligo Area Scoring Index 75 (F-VASI75) at Week 52 and Total body Vitiligo Area Scoring Index 50 (T-VASI50) at Week 52 |
| Registry ID | NCT06072183 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T02:32:20.027Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT06072183
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.